Table 5.
Factors independently associated with receiving 12 compared with 8 weeks of ledipasvir/sofosbuvir among 2653 HCV-infected individuals eligible for 8 weeks
| Adjusted RR (95% CI) | P | |
|---|---|---|
| Black race (ref: non-Black) | 0.98 (0.84–1.14) | 0.81 |
| Age ≥50 years | 1.05 (0.85–1.31) | 0.65 |
| Male | 1.39 (1.22–1.58) | <0.001 |
| Transient elastography kPa ≥9.5 or FIB-4 ≥1.45 | 3.29 (2.82–3.85) | <0.001 |
| International normalized ratio >1.1 | 1.37 (1.18–1.59) | <0.001 |
| Bilirubin >1.1 g/dL | 1.51 (1.31–1.75) | <0.001 |
| Albumin <3.6 g/dL | 1.28 (1.14–1.44) | <0.001 |
| Body mass index >30 kg/m2 | 1.40 (1.23–1.60) | <0.001 |
| Diabetes | 0.98 (0.84–1.14) | 0.81 |
| Alcoholic drinks per week (ref: 0) | ||
| 1–7 | 0.75 (0.60–0.93) | 0.009 |
| 8–14 | 0.99 (0.69–1.43) | 0.96 |
| ≥15 | 1.40 (1.06–1.84) | 0.017 |
| Hepatitis B virus infection | 1.01 (0.81–1.26) | 0.90 |
HCV, hepatitis C virus; RR, risk ratio; CI, confidence interval. Eligibility for 8 weeks was defined as genotype 1, treatment-naive, no cirrhosis (i.e., transient elastography <12 kPa if available, else FIB-4 ≤5.88), HIV-uninfected, and HCV RNA <6 million IU/mL. RRs obtained from Poisson models with robust variance, including terms for all variables listed in the table.